SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Theravance - THRX -- Ignore unavailable to you. Want to Upgrade?


To: kenhott who wrote (28)8/23/2006 7:52:14 AM
From: rkrw  Read Replies (1) | Respond to of 74
 
Approval is noninferiority as it is for all antibiotic trials. Superiority in mrsa was separate and not a gating issue to approval, that was the HR shot.



To: kenhott who wrote (28)8/25/2006 9:42:50 AM
From: Biomaven  Read Replies (2) | Respond to of 74
 
The p value needed to show superiority in these trials maybe less than .05

Actually they needed .025 for some reason - I don't recall seeing a full discussion of the trial design so I'm not sure why.

Peter